Brilinta and Ninlaro drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Brilinta (ticagrelor) and Ninlaro (ixazomib citrate). Common drug interactions include soft tissue infection among females and diarrhoea among males.
The phase IV clinical study analyzes what interactions people have when they take Brilinta and Ninlaro. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.
What is Brilinta?
Brilinta has active ingredients of ticagrelor. It is often used in stent. eHealthMe is studying from 22,469 Brilinta users. Check the latest studies of Brilinta.
What is Ninlaro?
Ninlaro has active ingredients of ixazomib citrate. eHealthMe is studying from 19,563 Ninlaro users. Check the latest studies of Ninlaro.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
16 people who take Brilinta and Ninlaro together, and have interactions are studied.
What are the common drug interactions of Brilinta and Ninlaro, by gender? *:
female:
- Soft tissue infection
- Pneumonia
male:
- Diarrhoea
- Chest pain
- Nausea (feeling of having an urge to vomit)
- Neuropathy peripheral (surface nerve damage)
- Accident
- Death
- Drug ineffective
- Muscle spasms (muscle contraction)
- Upper respiratory tract infection
What are the common drug interactions of Brilinta and Ninlaro, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
n/a
40-49:
n/a
50-59:
n/a
60+:
- Diarrhoea
- Accident
- Death
- Drug ineffective
- Pneumonia
What are the existing conditions these people have? *
- Multiple Myeloma (cancer of the plasma cells): 16 people, 100.00%
- Diabetes: 1 person, 6.25%
* Approximation only. Some reports may have incomplete information.
Do you take Brilinta and Ninlaro?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Brilinta and Ninlaro:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Brilinta:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Ninlaro:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Brilinta and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Ninlaro and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study uses data from the FDA. It is based on ticagrelor and ixazomib citrate (the active ingredients of Brilinta and Ninlaro, respectively), and Brilinta and Ninlaro (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Vitamins and Saccharomyces Boulardii - now
- Could Theophyl cause Eye Swelling? - 3 seconds ago
- Could Methotrexate cause Myocarditis? - 3 seconds ago
- Could Simvastatin cause Acinetobacter Infection? - 8 seconds ago
- Could Velcade cause Aggression Aggravated? - 11 seconds ago
- Could Citalopram Hydrobromide cause Sciatica Aggravated? - 17 seconds ago
- Could Gilotrif cause Mouth Ulcers? - 22 seconds ago
- Could Forteo cause Radiculopathy? - 25 seconds ago
- Meperidine Hydrochloride vs. Vivitrol, side effect and effectiveness comparison - 26 seconds ago
- Drug interactions of Edarbyclor and Revlimid - 29 seconds ago